Germans are most afraid of cancer (67%). Correspondingly important to them is cancer research, which in their view is driven above all by academic research institutions (80%). The biggest innovation drivers in cancer research, alongside established oncologists (30%), are clinics (26%) and research-based pharmaceutical companies (25%).
Eight out of ten Germans support the use of personalized patient data if it helps to develop cancer drugs more quickly. More than three-quarters of them would also be willing to share their own personal data for cancer research with a trustworthy institution. These include, primarily, the main drivers of innovation – academic research institutions (64%), oncologists (53%) and clinics (42%).
In return for providing personal data, just under one in five expect financial compensation, e.g. in the form of lower health insurance contributions or a payment. One third, however, would provide data for free. More than a quarter of Germans would even welcome the need to make anonymous provision of data mandatory.
In addition to sharing personal data, two-thirds of Germans would be willing to support cancer research by participating in studies. Asked about making further financial contributions (donations, additional health insurance contribution), Germans show significantly less support.
Even though the costs of modern drug cancer therapy, at easily more than 50,000 euros per year and patient, exceed the average cost per insured person twelve-fold, six out of ten Germans consider these expenses to be justified, especially where the medical benefits of innovative medicine are proven.
Three quarters of Germans support increased expansion of centers of excellence for cancer medicine, e.g. for breast cancer or leukemia.
Michael Burkhart, Head of Healthcare & Pharma at PwC Deutschland, and Dr. Thomas Solbach, Pharma and Health expert at Strategy& Germany, explain their interpretation of the findings in this interview.
The report presents the results of an online population survey on "Personalized Cancer Medicine“, which was commissioned by PricewaterhouseCoopers GmbH WPG.